Axonics R20 Post-Market Clinical Follow-up (PMCF)-undersøgelse for indikationen fekalincontinens
Postmarkedsføringsklinisk opfølgningsundersøgelse af det genopladelige Axonics SNM-system INS-model 5101 (R20) til indikationen fekalincontinence (FI)
Single-Arm, multi-center, prospective, open-label registry study for commercially available rechargeable implantable neurostimulator (INS model 5101); also referred to as R20.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Post-market clinical follow-up for continued assessment of safety and performance of the Axonics INS Model 5101 (R20). The study will include participants with the primary diagnosis of fecal incontinence who are eligible to receive the rechargeable R20 device as per the commercially available IFU.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Caroline Beaudoint
- Telefonnummer: +32 (0) 479 90.41.63
- E-mail: caroline.beaudoint@bsci.com
Undersøgelse Kontakt Backup
- Navn: Gita Ghadimi, OD
- Telefonnummer: 1-949-981-4366
- E-mail: gita.ghadimi@bsci.com
Studiesteder
-
-
-
Sheffield, Det Forenede Kongerige
- Rekruttering
- Northern General Hospital
-
Kontakt:
- Caroline Steele
-
Ledende efterforsker:
- Keith Chapple, Mr.
-
-
-
-
New York
-
New York, New York, Forenede Stater, 10032
- Rekruttering
- Columbia University Medical Center
-
Ledende efterforsker:
- Marco B. Zoccali, MD
-
Kontakt:
- Emily Breneisen
- E-mail: eb3709@cumc.columbia.edu
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater, 45219
- Rekruttering
- The Christ Hospital
-
Kontakt:
- Sharon Lamping, CCRC
-
Ledende efterforsker:
- Rodger Rothenberger, MD
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37209
- Rekruttering
- Female Urology of Nashville Research Partnership
-
Ledende efterforsker:
- Ly Hoang Roberts, MD
-
Kontakt:
- Esha Ramjee
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- Houston Colon
-
Kontakt:
- Jimena Alcocer-Barrios
- E-mail: jalcocerbarrios@houstoncolon.com
-
Ledende efterforsker:
- Eric M. Haas, MD
-
San Antonio, Texas, Forenede Stater, 78258
- Aktiv, ikke rekrutterende
- Sonterra Procedure Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Adults aged 18 or older, diagnosed with FI as indicated per commercially available IFU.
Beskrivelse
Inclusion Criteria:
- 18 years or older
- Primary indication of Fecal Incontinence (FI)
- Willing and capable to provide informed consent and agrees to comply with specified evaluations at selected clinical centers
Exclusion Criteria:
- Any significant medical condition that is likely to interfere with study procedures, device operation, or likely to confound evaluation of study endpoints (includes neurological conditions such as multiple sclerosis)
- Any psychiatric or personality disorder at the discretion of the study participating physician; this may include poor understanding or compliance with trial requirements
- History of allergic response to titanium, zirconia, polyurethane, epoxy, or silicone
- A female who is breastfeeding
- A female with a positive urine pregnancy test
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: CASE_ONLY
- Tidsperspektiver: PROSPECTIVE
Antal grupper/kohorter
Kohorter og interventioner
Gruppe / kohorteGruppe / kohorte |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Fecal Incontinence
Participants with the Axonics SNM System Model 5101 and followed up regarding their fecal incontinence symptoms. |
Participants treated with the rechargeable Axonics SNM System Model 5101 also referred to as R20. Commercial devices used in this study are within their intended use as described in each geography's approved instructions for use. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Performance/effectiveness - Improvement in Quality of Life scoring (FI)
Tidsramme: 3 months
|
Short-term FI improvement demonstrated by Cleveland Clinic Florida Fecal Incontinence Score (CCF-FIS). Cleveland Clinic Florida - Fecal Incontinence Score (CCF-FIS): scores range from 0 for full continence to 20 for complete incontinence. A higher score is indicative of the severity of fecal incontinence. |
3 months
|
|
Performance/effectiveness - Improvement in patient satisfaction scoring (FI)
Tidsramme: 3 months
|
Short-term FI improvement demonstrated by Participant Satisfaction with Treatment and Charging Questionnaire. Participants will indicate satisfaction with SNM therapy for treatment of their FI symptoms based on a 7-point Likert scale ranging from "Very satisfied" to "Very dissatisfied". |
3 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Performance/effectiveness - Improvement in Quality of Life scoring (FI)
Tidsramme: 12 months
|
Demonstrate any improvement in CCF-FIS at 1-year post-implant compared to baseline. Cleveland Clinic Florida - Fecal Incontinence Score (CCF-FIS): scores range from 0 for full continence to 20 for complete incontinence. A higher score is indicative of the severity of fecal incontinence. |
12 months
|
|
Performance/effectiveness - Improvement in Quality of Life scoring (FI)
Tidsramme: 3 months, 12 months
|
Demonstrate an improvement in Fecal Incontinence Quality of Life (FIQOL) at 3 months, and 1-year post-implant compared to baseline. Fecal Incontinence Quality of Life (FIQOL) includes four different subscales: lifestyle, coping/behavior, depression/self-perception and embarrassment. Subscale scores range from 1 to 5, with 1 indicating lower functional status of qualify of life. |
3 months, 12 months
|
|
Performance/effectiveness - Improvement in patient satisfaction scoring (FI)
Tidsramme: 12 months
|
Participant Satisfaction with Treatment and Charging Questionnaire at 1-year post-implant compared to baseline. Participants will indicate satisfaction with SNM therapy for treatment of their FI symptoms based on a 7-point Likert scale ranging from "Very satisfied" to "Very dissatisfied". |
12 months
|
|
Adverse event reporting (Safety)
Tidsramme: 3 months, 12 months
|
Device related, procedure-related and all serious adverse events |
3 months, 12 months
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Ledende efterforsker: Keith Chapple, MD, Sheffield Teaching Hospitals NHS Foundation Trust
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 105-0169
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .